TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30427135
Drug: Dermal equivalent
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal equivalent (DE) applied on trophic ulcers in addition to standard treatment
Study: 18662287
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg b.d.
Study: 9613910
Drug: Lovastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20-40 mg daily)
Study: 29031763
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate treatment in SXB-15
Study: 29031763
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate treatment in SXB-22
Study: 25934164
Drug: LNG20 (52-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG20 (52-mg levonorgestrel intrauterine contraceptive)
Study: 23857972
Drug: Sunitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib plus capecitabine (2,000 mg/m2)
Study: 3961002
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hydrocortisone
Study: 23945999
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg hydrocortisone
Study: 17143357
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 0.5 g/kg over 4 hours, every 12 hours for 3 doses
Study: 14673697
Drug: Transdermal absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal absorption of estradiol in normal subjects
Study: 14673697
Drug: Transdermal absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal absorption of estradiol in patients with polyneuropathy
Study: 10871969
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin treatment at home
Study: 10871969
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin treatment in hospital
Study: 9663831
Drug: Lactulose 5
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose 5 g
Study: 9663831
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 g
Study: 8200722
Drug: Seaprose (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seaprose (90 mg/day for 10 days)
Study: 24834887
Drug: 500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg iodine load and 80 kV(p) tube voltage
Study: 24834887
Drug: 400 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/kg iodine load and 80 kV(p) tube voltage
Study: 24834887
Drug: 600 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/kg iodine load and 120 kV(p) tube voltage
Study: 12395978
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg alone
Study: 16022753
Drug: Galactose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactose (50 g)/guar gum (2.5 g) load with standard breakfast (GG)
Study: 16022753
Drug: Water (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (250 ml) with standard breakfast (W)
Study: 1826823
Drug: Medroxy progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medroxy progesterone acetate 500 mg i.m. twice weekly for 3 months
Study: 29952137
Drug: Combined inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inspiratory and expiratory external resistance (2-20 cmH2 O/L/sec)
Study: 27802950
Drug: Family Navigator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Navigator (FN) intervention with daily contact addressing informational and emotional communication needs.
Study: 5531862
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol
Study: 5531862
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol in a patient with a completely denervated hand
Study: 29259181
Drug: Fresh fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh fish (250 g twice weekly for 8 weeks)
Study: 25780304
Drug: PEG‐Asc (2‐L
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐Asc (2‐L polyethylene glycol with ascorbic acid 20 g)
Study: 22632135
Drug: Psycho-educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-educational program for caregivers (10 sessions of 90 minutes over 5 weeks) + antipsychotic drug treatment for patients
Study: 19253021
Drug: Maitake liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maitake liquid extract at 0.1, 0.5, 1.5, 3, or 5 mg/kg twice daily for 3 weeks
Study: 17312364
Drug: Skin protection
Normalized name: NeutrapHor 1% Skin Protection Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin protection ointment
Study: 12234565
Drug: High-dose LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose LMWH for thromboprophylaxis for the first postoperative week
Study: 10212537
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants in the posterior region of the maxilla
Study: 10212537
Drug: Clinical parameters
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical parameters (bleeding, pocket depth, implant mobility)
Study: 508702
Drug: Intramuscular Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Fe dextran, 100 mg twice per week for 10-12 weeks
Study: 508702
Drug: Oral Fe,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Fe, 120 mg/d, 6 d/week for 10-12 weeks
Study: 508702
Drug: Intravenous Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Fe by total dose infusion of Fe dextran
Study: 10065696
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 400 microg
Study: 10065696
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 400 microg plus oral activated charcoal
Study: 2394068
Drug: Femoral vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral vein infusion with single location dynamic scanning
Study: 20448359
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salvia miltiorrhiza and prednisolone
Study: 12033092
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg‐1 and fentanyl 2 micrograms.kg‐1
Study: 10087242
Drug: Prempak C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prempak C 0.625(R) hormone replacement therapy
Study: 8649914
Drug: Nebulised budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised budesonide (2 mg)
Study: 7018726
Drug: MER (methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: MER (methanol extraction residue BCG) immunotherapy during chemotherapy
Study: 22806399
Drug: Apremilast 40
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 40 mg once per day (treatment-extension phase)
Study: 8782347
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of antigen) administered according to the abbreviated schedule (two vaccinations given 2 weeks apart)
Study: 8782347
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of antigen) administered according to the standard schedule (two vaccinations given 4 weeks apart)
Study: 8782347
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of antigen)
Study: 8782347
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of antigen) with other 'travellers' vaccines
Study: 1509550
Drug: Propofol (Diprivan)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (Diprivan) without prior administration of fentanyl
Study: 6838691
Drug: Diet and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and/or drugs
Study: 24949549
Drug: SOD-melon concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOD-melon concentrate (10 mg per day for 12 weeks)
Study: 28510491
Drug: Extra-fine BDP
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-fine BDP breath-actuated inhaler (Aerobec®/QVAR® Autohaler®) 100 μg b.i.d.
Study: 23972645
Drug: Uncoated mini‐tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoated mini‐tablets
Study: 23972645
Drug: Coated mini‐tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated mini‐tablet
Study: 17823672
Drug: Buprenorphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (1 mL injected into the joint space)
Study: 17823672
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 mL injected into the joint space)
Study: 2177041
Drug: Itraconazole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (4 mg per 1 kg of body weight, once daily for 6 weeks)
Study: 6996516
Drug: Alcohol (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (three doses) during luteal phase
Study: 26262586
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training plus low dose of dopamine agonists (DA)
Study: 15606570
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide 100 microg
Study: 11438328
Drug: 0.060 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.060 mg Org 30659
Study: 11438328
Drug: 0.120 mg
Normalized name: ETONOGESTREL 0.120 mg in 1 d / ETHINYL ESTRADIOL 0.015 mg in 1 d VAGINAL RING [EluRyng]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.120 mg Org 30659
Study: 28472240
Drug: Goserelin (gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (gonadotropin-releasing hormone agonist) administered before and during chemotherapy
Study: 26035199
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg venlafaxine + 60‐minute light of 7000 lux daily at 7:00 AM (venlafaxine + bright light therapy)
Study: 26035199
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg venlafaxine daily at 7:00 AM
Study: 21251178
Drug: LY2189265 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2189265 (LY) 1 mg or higher doses
Study: 21251178
Drug: LY2189265 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2189265 (LY) 0.3 mg
Study: 21251178
Drug: LY2189265 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2189265 (LY) 0.05, 0.3, 1, 3, 5, or 8 mg
Study: 19254299
Drug: Deliberate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deliberate prescription of impression materials
Study: 9314089
Drug: Tiazac (diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiazac (diltiazem HCl capsule formulation)
Study: 9314089
Drug: Cardizem CD
Normalized name: Cardizem CD
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardizem CD (extended-release diltiazem)
Study: 9314089
Drug: Dilacor XR
Normalized name: Dilacor XR
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilacor XR (extended-release diltiazem)
Study: 2195863
Drug: Dipyridamole 150
Normalized name: dipyridamole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 150 mg/day
Study: 24224449
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (vitamin C) supplementation at a dose of 600 mg per 24 hours during chemotherapy
Study: 16979993
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) [1.5-2.0 g/d]
Study: 10938494
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate CR/XL added to standard therapy
Study: 9052464
Drug: Intravesical pentosanpolysulphate
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical pentosanpolysulphate (PPS) 300 mg in 50 mL of 0.9% sodium chloride, applied twice a week for 3 months
Study: 8398961
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine (5 mg in 25 ml dilution)
Study: 8398961
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (25 ml saline)
Study: 3742049
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg/d for 8 weeks)
Study: 28480658
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with Alendronate (ALEN) and Hormonal Therapy (HT)
Study: 19383314
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor receptor inhibitors
Study: 16621768
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine supplementation (4 g/m2/day) during chemotherapy
Study: 2227076
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ursodeoxycholic acid (UDCA) twice daily for 14 days
Study: 30190512
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy (ADV-TK, 5 × 10^12/ml) administered one or two times before operation
Study: 26620101
Drug: BIT225 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIT225 (400 mg twice daily)
Study: 10172545
Drug: Control district
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control district with only government drug supply
Study: 31109368
Drug: TMQLB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMQLB group 1 (0.4 ml/kg body weight 0.5% ropivacaine)
Study: 31109368
Drug: TMQLB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMQLB group 2 (0.6 ml/kg body weight 0.5% ropivacaine)
Study: 31109368
Drug: TPVB control
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPVB control group (0.4 ml/kg body weight 0.5% ropivacaine at vertebra T10)
Study: 23954912
Drug: Oral α‐methyl‐para‐tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral α‐methyl‐para‐tyrosine (catecholamine depletion)
Study: 21471564
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (vinorelbine-cisplatin)
Study: 9708399
Drug: SQV-SGC 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV-SGC 1200 mg three times a day for 16 weeks
Study: 9708399
Drug: SQV-HGC 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV-HGC 600 mg three times a day for 16 weeks
Study: 27568322
Drug: Trastuzumab in
Normalized name: trastuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab in combination with cisplatin and fluoropyrimidines
Study: 25048952
Drug: Avatrombopag (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag (100mg loading dose followed by 20, 40, or 80 mg/day on days 2‐7)
Study: 25048952
Drug: Avatrombopag (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag (80 mg loading dose followed by 10 mg/day for days 2‐7, or 20mg/day for days 2‐4)
Study: 20018286
Drug: Rosuvastatin 20mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20mg/daily
Study: 20018286
Drug: Simvastatin 20mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20mg/daily
Study: 19543080
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg/day) at bedtime
Study: 12714817
Drug: 5-FU (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (60 mg/kg body weight) for 48 hours
Study: 12714817
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (FA) (500 mg/m2) for 2 hours and 5-FU (2600 mg/m2) for 24 hours
Study: 29534310
Drug: Non-CC genotype
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-CC genotype patients
Study: 22652101
Drug: Silver clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver clear nylon dressing (SCND) applied from Day 1 of radiation therapy until 2 weeks after treatment completion
Study: 22652101
Drug: Standard skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard skin care (sulfadiazine cream applied at the time of skin dermatitis)
Study: 20590587
Drug: Oxycodone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.2 mg x kg(‐1) + Quinidine (CYP2D6 inhibitor)
Study: 20590587
Drug: Oxycodone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.2 mg x kg(‐1) + Quinidine + Ketoconazole
Study: 10411811
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (50 mg/m²)
Study: 6940435
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol diet (1400 mg cholesterol/day)
Study: 6940435
Drug: Normal cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal cholesterol diet (400 mg cholesterol/day)
Study: 11216321
Drug: Hypnotic procedures
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic procedures at testing
Study: 27296705
Drug: Atorvastatin/ezetimibe combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin/ezetimibe combination
Study: 29096836
Drug: Atorvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin alone
Study: 21464053
Drug: β-blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker use
Study: 16023653
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE)
Study: 12546339
Drug: TAA nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA nasal spray 110 microg
Study: 12546339
Drug: TAA nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA nasal spray 220 microg
Study: 8889902
Drug: Yohimbine hydrochloride,
Normalized name: Yohimbine Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride, single oral doses up to 21.6 mg
Study: 8889902
Drug: Yohimbine hydrochloride,
Normalized name: Yohimbine Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride, single oral doses
Study: 8889902
Drug: Yohimbine hydrochloride,
Normalized name: Yohimbine Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride, higher doses
Study: 8889902
Drug: Yohimbine hydrochloride,
Normalized name: Yohimbine Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride, administration with high fat meal
Study: 31797203
Drug: Icotinib combined
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib combined with local radiotherapy and subcutaneous injection of GM-CSF
Study: 18201581
Drug: Ropinirole 24-hour
Normalized name: ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole 24-hour prolonged release 8 mg QD
Study: 18201581
Drug: Ropinirole 24-hour
Normalized name: ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole 24-hour prolonged release (2-, 4-, and 8-mg tablets)
Study: 15197192
Drug: IV vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vinorelbine 25 mg/m(2) on days 1 and 8 plus IV epirubicin 90 mg/m(2) on day 1
Study: 8575054
Drug: Pancuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.1 mg/kg)
Study: 20053325
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with alefacept
Study: 17513945
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy (hydrochlorothiazide 25 mg plus amiloride 5 mg)
Study: 15551394
Drug: Solanum xanthocarpum
Normalized name: solanum xanthocarpum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solanum xanthocarpum and Solanum trilobatum (300 mg tds for 3 days)
Study: 11435848
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (noncontact neodymium (Nd):YAG visual laser assisted prostatectomy)
Study: 8750567
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin
Study: 29798480
Drug: Unilateral A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral A group (only cochlear implant)
Study: 20507953
Drug: Intensive renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive renal replacement therapy
Study: 17090995
Drug: Daily fluid
Normalized name: ENSULIZOLE 4 g in 100 mL / OCTINOXATE 5 g in 100 mL / OCTOCRYLENE 10 g in 100 mL / TITANIUM DIOXIDE 5 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL CREAM [EXEL CLARIFYING LINE DAILY FLUID SUN SHIELD WHITE COLOR BROAD SPECTRUM SPF 60 PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fluid intake measurement (1,035 ml average, SD=359 ml, range 210 ml to 2,050 ml)
Study: 4025160
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker therapy (verapamil or nifedipine)
Study: 29722846
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (2 oral doses of 200,000 IU at 2 and 4 weeks)